Letter to the Editor

被引：37

作者：

Hastings, KL ^{[1
]}

El-Hage, J ^{[1
]}

Jacobs, A ^{[1
]}

Leighton, J ^{[1
]}

Morse, D ^{[1
]}

Osterberg, RE ^{[1
]}

机构：

[1] US FDA, Ctr Drug Evaluat & Res, Off New Drugs, Rockville, MD 20857 USA

来源：

TOXICOLOGY AND APPLIED PHARMACOLOGY | 2003年 / 190卷 / 01期

关键词：

D O I：

10.1016/S0041-008X(03)00150-9

中图分类号：

R9 [药学];

学科分类号：

1007 ;

摘要：

引用

页码：91 / 92

页数：2

共 8 条

[1]

[Anonymous], 2002, IMP NEW DRUG SUBST

[2] Drug metabolites in safety testing [J].

Baillie, TA ;

Cayen, MN ;

Fouda, H ;

Gerson, RJ ;

Green, JD ;

Grossman, SJ ;

Klunk, LJ ;

LeBlanc, B ;

Perkins, DG ;

Shipley, LA .

TOXICOLOGY AND APPLIED PHARMACOLOGY, 2002, 182 (03) :188-196

[3]

CALLIS AH, 1986, MOL CELLULAR MECHANI, P443

[4]

CROY RG, 1981, CANCER RES, V41, P197

[5] MECHANISM OF HALOTHANE-INDUCED LIVER-INJURY - IS IT IMMUNE OR METABOLIC IDIOSYNCRASY [J].

FARRELL, GC .

JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY, 1988, 3 (05) :465-482

[6] Forging the links between metabolism and carcinogenesis [J].

Guengerich, FP .

MUTATION RESEARCH-REVIEWS IN MUTATION RESEARCH, 2001, 488 (03) :195-209

[7]

*US EPA, 1998, 8707485 US EPA OPPTS

[8]

*US FDA, 2002, GUID MET STUD SEL RE

← 1 →